Coronavirus – South African Study: J&J booster dose is 84% ​​effective against hospitalization

A booster dose of Johnson & Johnson’s single-dose coronavirus vaccine was 84% ​​effective in preventing hospitalization as the Omicron variant spreads, researchers said on Thursday, according to Reuters.

The study, which has not been peer-reviewed, was based on a second dose of the J&J vaccine given to 69,092 healthcare workers between November 15 and December 20.

According to the report, an initial vaccination has been shown to offer significantly reduced protection against Omicron, especially against infection. However, several studies have shown that a booster dose still provides significant protection against serious illness.

A new South African study of the J&J vaccine found that the vaccine’s effectiveness in preventing hospitalization increased from 63% shortly after the booster vaccine to 84% 14 days later. The efficacy reached 85% one to two months after the booster dose.

Earlier this month, another South African study found that a first round of two doses of the Pfizer-BioNTech vaccine was less effective in South Africa in preventing people infected with coronavirus from developing the Omic variant. last month.

It is recalled that scientists in South Africa first notified the World Health Organization that they had detected Homicron in late November.